EcoDrugPlus

Sem1 26s Proteasome Subunit

Ensembl ID : ENSCGOG00000011968
Gene Symbol: SEM1
1 Cross references
156 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCGOG00000022172
Gene Symbol: SRC
3 Cross references
191 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSCGOG00000013078
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSCGOG00000004017
Gene Symbol: WEE1
3 Cross references
206 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSCGOG00000007440
Gene Symbol: YES1
3 Cross references
197 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSCGOG00000011458
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSCGOG00000014343
Gene Symbol: ACVR2B
3 Cross references
196 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSCGOG00000006496
Gene Symbol: ADORA1
3 Cross references
208 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSCGOG00000022558
Gene Symbol: ADORA2A
3 Cross references
200 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSCGOG00000008022
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSCGOG00000000673
Gene Symbol: ADORA3
3 Cross references
228 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSCGOG00000004781
Gene Symbol: ADA
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).